Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 2Phase 4 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Graft vs Host Disease 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 49Cyclophosphamide 28venetoclax 24Bendamustine Hydrochloride 24obinutuzumab 22ibrutinib 21Chlorambucil 20fludarabine 16fludarabine phosphate 15idelalisib 13acalabrutinib 11pirtobrutinib 7ofatumumab 7zanubrutinib 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Cyclosporine 5Radiotherapy 4Prednisone 4Doxorubicin 4duvelisib 3Whole-Body Irradiation 3Specimen Handling 3Methotrexate 3Lenalidomide 3Filgrastim 3Epoetin Alfa 3Cyclosporins 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Lymphocytic, Chronic, B-Cell × Pentostatin × Clear all
NCT00254163 2016-11-03

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

US Oncology Research

Phase 3 Completed
184 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡